News Releases
-
MONTREAL, QUEBEC – October 26, 2010
Newest Treatment for Schizophrenia & Related Psychotic Disorders now Available to all Quebecers
ABILIFY™ reimbursed as a full benefit on the Quebec drug plans
Categories: Abilify | Schizophrenia
-
MONTREAL, QC, and TORONTO, ON - November 12, 2009
Health Canada Approves New Treatment for Adults With Type 2 Diabetes
ONGLYZA™ (saxagliptin) approval coincides with new research that shows 91 per cent of Canadians with diabetes are drifting in the management of their disease
-
MONTREAL, QUEBEC — October 6, 2009
Latest Treatment for Schizophrenia Offers Needed Additional Option to Fight Difficult-To-Treat Disease
ABILIFY™ now available in Canada with several benefits: efficacy, good safety, tolerability and neutral impact on weight, cholesterol and blood sugar levels
Categories: Abilify | Schizophrenia
-
MONTREAL, CANADA — September 30, 2009
Erbitux™ Now Available in Ontario and BC for Patients With Advanced Colorectal Cancer
Categories: Erbitux | Metastatic colorectal cancer
-
MONTREAL, CANADA – June 12, 2009
Bristol-Myers Squibb Employees Give Back to the Community
Over 300 employees across Canada take part in second annual Community Action Day
Categories: Community
-
MONTREAL, CANADA – May 28, 2009
Montreal Mayor Gérald Tremblay Joins Bristol-Myers Squibb in Presenting Trees to Local Saint-Laurent Schools
A unique green way to inaugurate company's new offices in Montreal's Technoparc
Categories: Company
-
MONTREAL, CANADA — March 19, 2009
Bristol-Myers Squibb Canada relocates to Technoparc Montreal
Prominent R&D address to become new home for Canadian headquarters
Categories: Company
-
MONTREAL, CANADA — December 15, 2008
Lower Dose Sprycel™ Approved for Patients With Chronic Phase CML
New once daily dose retains efficacy and improves tolerability
Categories: Chronic myeloid leukemia (CML) | Sprycel
-
MONTREAL, CANADA — October 29, 2008
Bristol-Myers Squibb Canada Commercializes Erbitux™ for Advanced Colorectal Cancer
ERBITUX offers patients a new option for treating the disease and receives approval from Health Canada for the treatment of head and neck cancer
Categories: Erbitux | Metastatic colorectal cancer
-
MONTREAL, CANADA — February 7, 2008
CASTLE Study Showed Similar Efficacy Between Once-Daily Reyataz® (atazanavir sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Data also showed differences in gastrointestinal and lipid effects between REYATAZ/ritonavir and lopinavir/ritonavir among study population
-
LAVAL (QUEBEC), CANADA — June 5, 2007
Health Canada's Approval of an Expanded Indication for Plavix® (Clopidogrel Bisulfate) Now Offers Protection from All Types of Heart Attacks
Categories: Cardiovascular | Plavix
-
MONTREAL, CANADA — May 17, 2007
Health Canada Approves Reyataz® (atazanavir sulfate) 300 mg Single Capsule Formulation in Combination Therapy for Adults With HIV-1 Infection
Formulation Marks The First One Capsule, Once Daily Protease Inhibitor Dosing Option for Use With Ritonavir In Appropriate Patients
-
MONTREAL, CANADA — March 28, 2007
Health Canada Approves Sprycel™, a New Treatment for Chronic Myeloid Leukemia
Molecular breakthrough offers new hope for patients with life-threatening form of blood cancer who fail or intolerant to current therapies
Categories: Chronic myeloid leukemia (CML) | Sprycel
-
CANDIAC (Quebec), CANADA - February 26, 2007
Bristol-Myers Squibb Consolidates its Candiac Clinical Supply Operations
Categories: Company
-
MONTREAL, CANADA — February 8, 2007
Quebec is the first province in Canada to reimburse new drug developed to treat chronic hepatitis B
Categories: Baraclude | Chronic hepatitis B
